| Not Yet Recruiting | RVU120 Rollover Study NCT06987058 | Ryvu Therapeutics SA | Phase 2 |
| Recruiting | A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias NCT06994676 | Crossbow Therapeutics, Inc. | Phase 1 |
| Active Not Recruiting | Safety and Efficacy of RVU120 for Treatment of Relapsed/Refractory AML NCT06268574 | Ryvu Therapeutics SA | Phase 2 |
| Recruiting | Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies NCT06034275 | Vincerx Pharma, Inc. | Phase 1 |
| Recruiting | The Patient Cohort of the National Center for Precision Medicine in Leukemia NCT05326919 | Assistance Publique - Hôpitaux de Paris | — |
| Unknown | A Study of APG-115 Alone or Combined With Azacitidine in Patients With AML, CMML, or MDS NCT04358393 | Ascentage Pharma Group Inc. | Phase 1 / Phase 2 |
| Recruiting | Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia an NCT04128748 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Active Not Recruiting | Total Marrow and Lymphoid Irradiation as Conditioning Regimen Before Hematopoietic Cell Transplantation in Pat NCT04262843 | City of Hope Medical Center | Phase 2 |
| Unknown | A Trial of Treatments to Assess the Effects on Outcome of Adults With AML and MDS Undergoing Allogeneic SCT NCT04217278 | University of Birmingham | Phase 2 / Phase 3 |
| Recruiting | Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Re NCT04047641 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Unknown | RVU120 in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome NCT04021368 | Ryvu Therapeutics SA | Phase 1 |
| Active Not Recruiting | Hu8F4 in Treating Patients With Advanced Hematologic Malignancies NCT02530034 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | Evaluating the Efficacy and Safety of Bemcentinib in Patients With Myelodysplastic Syndromes NCT03824080 | GWT-TUD GmbH | Phase 2 |
| Active Not Recruiting | Liposome-encapsulated Daunorubicin-Cytarabine and Gemtuzumab Ozogamicin in Treating Patients With Relapsed or NCT03672539 | M.D. Anderson Cancer Center | Phase 2 |
| Recruiting | Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndr NCT03630991 | M.D. Anderson Cancer Center | Phase 1 |
| Recruiting | Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood NCT03589729 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Decitabine, and Nivolumab in Treating Patients With Myelo NCT03358719 | Roswell Park Cancer Institute | Phase 1 |
| Completed | Glutaminase Inhibitor CB-839 and Azacitidine in Treating Patients With Advanced Myelodysplastic Syndrome NCT03047993 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Unknown | Azacitidine and Pembrolizumab in Treating Patients With Myelodysplastic Syndrome NCT03094637 | M.D. Anderson Cancer Center | Phase 2 |
| Terminated | Daratumumab in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplast NCT03067571 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractor NCT03263637 | AstraZeneca | Phase 1 |
| Recruiting | Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory A NCT03214562 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Active Not Recruiting | Busulfan, Fludarabine Phosphate, and Post-Transplant Cyclophosphamide in Treating Patients With Blood Cancer U NCT02861417 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Guadecitabine in Treating Patients With Higher-Risk Myelodysplastic Syndromes NCT02131597 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Pomalidomide After Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia o NCT02029950 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Donor Natural Killer Cells and Donor Stem Cell Transplant in Treating Patients With High Risk Myeloid Malignan NCT01823198 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Terminated | Tosedostat and Cytarabine or Azacitidine in Treating Older Participants With Acute Myeloid Leukemia or High Ri NCT01636609 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | A Trial to Establish the Feasibility of Combining Either the Tyrosine Kinase Inhibitor AC220,CXCR4 Inhibitor P NCT01236144 | Cardiff University | Phase 1 / Phase 2 |
| Completed | Study of Hypoxia-Activated Prodrug TH-302 to Treat Advanced Leukemias NCT01149915 | Threshold Pharmaceuticals | Phase 1 |
| Recruiting | Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Tre NCT00801489 | M.D. Anderson Cancer Center | Phase 2 |